Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables RefundsShares Issued
Ratios

Ligand Pharmaceuticals (LGNDZ) Non-Current Receivables (2017 - 2025)

Ligand Pharmaceuticals (LGNDZ) has disclosed Non-Current Receivables for 4 consecutive years, with $196.9 million as the latest value for Q4 2025.

  • Quarterly Non-Current Receivables rose 6.41% to $196.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $196.9 million through Dec 2025, up 6.41% year-over-year, with the annual reading at $196.9 million for FY2025, 6.41% up from the prior year.
  • Non-Current Receivables hit $196.9 million in Q4 2025 for Ligand Pharmaceuticals, down from $206.3 million in the prior quarter.
  • In the past five years, Non-Current Receivables ranged from a high of $206.3 million in Q3 2025 to a low of $2.5 million in Q2 2024.
  • Historically, Non-Current Receivables has averaged $144.4 million across 3 years, with a median of $188.3 million in 2025.
  • Biggest YoY gain for Non-Current Receivables was 7642.24% in 2025; the steepest drop was 3.55% in 2025.
  • Year by year, Non-Current Receivables stood at $62.3 million in 2023, then surged by 197.03% to $185.0 million in 2024, then grew by 6.41% to $196.9 million in 2025.
  • Business Quant data shows Non-Current Receivables for LGNDZ at $196.9 million in Q4 2025, $206.3 million in Q3 2025, and $193.6 million in Q2 2025.